HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information-Reference-Cited by-同舟云学术

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information

Published:2007-07-18 Issue:2 Volume:109 Page:351-357
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Rydén Lisa,Landberg Göran,Stål Olle,Nordenskjöld Bo,Fernö Mårten,Bendahl Pär-Ola

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-007-9660-2.pdf

Reference26 articles.

1. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER−2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

2. Borg A, Tandon AK, Sigurdsson H et al (1990) HER−2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332–4337

3. Press MF, Bernstein L, Thomas PA et al (1997) HER−2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15(8):2894–2904

4. Sjogren S, Inganas M, Lindgren A et al (1998) Prognostic and predictive value of c-erbB−2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462–469

5. Schmidt M, Lewark B, Kohlschmidt N et al (2005) Long-term prognostic significance of HER−2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 7(2):R256–266

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THE HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL PROFILE OF MALIGNANT BREAST TUMORS IN NORTH-EAST ROMANIA;Revista Medico-Chirurgicala;2023-03-31

2. Molecular and Immunohistochemical Alterations in Breast Cancer Patients in Upper Egypt;Reports of Biochemistry and Molecular Biology;2023-02-01

3. Impact of AJCC prognostic staging on prognosis and postmastectomy radiotherapy decision-making in hormone receptor-positive and HER2-positive breast cancer;BJS Open;2022-03-08

4. Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients;BMC Cancer;2021-07-13

5. Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer;BMC Cancer;2021-02-22